This article was originally published in The Gray Sheet
Executive SummaryOngoing share repurchase program will be doubled from 25 mil. to 50 mil. shares, the firm reports April 6. A total of 21.2 mil. shares already have been bought back under the program, which was implemented in October 1987. "Current market conditions have created an excellent opportunity to strengthen the company through a purchase of its own shares," BMS Chairman and CEO Richard Gelb states in a same-day release.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.